Evidence map›Paper›PMID 41923625›Full record

ArticleCell reports. Medicine2026

Identifying the role of NLRP3 inflammasome in stroke progression and outcome before recanalization.

Maximilian Bellut, Alexander M Kollikowski, Marius L Vogt, Lukas Rossnagel, Ibrahim Hawwari, Bernardo S Franklin, Mirko Pham, Guido Stoll, Michael K Schuhmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maximilian BellutUniversity Hospital Würzburg, Department of Neurology, Würzburg, Germany. Electronic address: bellut_m@ukw.de.
Alexander M KollikowskiUniversity Hospital Würzburg, Department of Neuroradiology, Würzburg, Germany.
Marius L VogtUniversity Hospital Würzburg, Department of Neuroradiology, Würzburg, Germany.
Lukas RossnagelInstitute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany.
Ibrahim HawwariInstitute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany.
Bernardo S FranklinInstitute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany.
Mirko PhamUniversity Hospital Würzburg, Department of Neuroradiology, Würzburg, Germany.
Guido StollUniversity Hospital Würzburg, Institute for Experimental Biomedicine, Würzburg, Germany.
Michael K SchuhmannUniversity Hospital Würzburg, Department of Neurology, Würzburg, Germany. Electronic address: schuhmann_m@ukw.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute ischemic stroke (AIS) induces a rapid inflammatory response that partly counteracts the beneficial effects of recanalization by endovascular thrombectomy (EVT). The molecular triggers of inflammation in AIS are still elusive. We analyze the role of the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome before recanalization. NLRP3-mRNA levels increase rapidly in the ischemic brain following permanent middle cerebral artery occlusion in mice. NLRP3 protein is primarily expressed by intravascular neutrophils and cerebral endothelium. Blocking NLRP3 activation with the small molecule MCC950 reduces infarct progression and inflammation significantly already during large vessel occlusion. In human AIS, we find similarly increased NLRP3 expression in accumulating leukocytes within pial blood samples taken from the secluded ischemic brain territory immediately before recanalization. The number of NLRP3-positive cells before EVT predicts stroke outcome after 3 months. Our results identify NLRP3 as a promising therapeutic target to attenuate rapid infarct progression prior to recanalization.

Indexed as

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinStrokeAnimalsDisease ProgressionFuransHumansIndenesInfarction, Middle Cerebral ArteryMaleMiceMice, Inbred C57BLNeutrophilsSulfonamidesFuransIndenesInflammasomesN-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamideNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseSulfonamidesacute ischemic strokeAISendovascular thrombectomyEVTinfarct progressioninterleukin 1βlarge vessel occlusionLVOMCAOMCC950middle cerebral artery occlusionneutrophilsNLRP3 inflammasomeNLRP3 inhibitorpial blood sampling

Identifiers

PMID41923625
PMCPMC13130646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.